BCRX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-25 | 2022 | Charles K. Gayer Chief Commercial Officer | 448,700 | 0 | 361,420 | 179,480 | 15,250 | 2,198,862 |
| 2024-04-25 | 2023 | Anthony J. Doyle Chief Financial Officer and Treasurer | 528,297 | 0 | 218,620 | 301,129 | 16,500 | 1,790,349 |
| 2024-04-25 | 2023 | Charles K. Gayer Chief Commercial Officer | 495,300 | 0 | 218,620 | 282,321 | 16,500 | 1,738,544 |
| 2024-04-25 | 2022 | Alane P. Barnes Chief Legal Officer and Corporate Secretary | 457,200 | 0 | 361,420 | 182,880 | 15,250 | 2,210,762 |
| 2024-04-25 | 2023 | Alane P. Barnes Chief Legal Officer and Corporate Secretary | 495,700 | 0 | 411,520 | 282,549 | 16,500 | 1,932,072 |
| 2024-04-25 | 2021 | Helen M. Thackray, M.D. Chief R&D Officer | 425,125 | 236,500 | 1,519,920 | 298,125 | 6,625 | 6,881,396 |
| 2024-04-25 | 2022 | Helen M. Thackray, M.D. Chief R&D Officer | 554,200 | 0 | 861,030 | 277,100 | 12,700 | 3,497,932 |
| 2024-04-25 | 2023 | Helen M. Thackray, M.D. Chief R&D Officer | 576,368 | 0 | 327,930 | 383,285 | 16,500 | 2,393,933 |
| 2024-04-25 | 2021 | Anthony J. Doyle Chief Financial Officer and Treasurer | 490,800 | 19,632 | 857,250 | 220,860 | 14,500 | 2,890,803 |
| 2024-04-25 | 2022 | Anthony J. Doyle Chief Financial Officer and Treasurer | 507,978 | 0 | 361,420 | 203,191 | 15,250 | 2,281,851 |
| 2024-04-25 | 2023 | Jon P. Stonehouse President, Chief Executive Officer and Director | 665,600 | 0 | 819,825 | 537,472 | 30,257 | 4,777,778 |
| 2024-04-25 | 2022 | Jon P. Stonehouse President, Chief Executive Officer and Director | 640,000 | 0 | 1,355,325 | 480,000 | 25,415 | 6,982,994 |
| 2024-04-25 | 2021 | Jon P. Stonehouse President, Chief Executive Officer and Director | 583,495 | 43,762 | 1,405,890 | 492,324 | 24,665 | 7,061,225 |
| 2023-04-27 | 2021 | Helen M. Thackray, M.D. Chief R&D Officer | 425,125 | 236,500 | 1,519,920 | 298,125 | 6,625 | 6,881,396 |
| 2023-04-27 | 2021 | Jon P. Stonehouse President, Chief Executive Officer and Director | 583,495 | 43,762 | 1,405,890 | 492,324 | 24,665 | 7,061,225 |
| 2023-04-27 | 2020 | Jon P. Stonehouse President, Chief Executive Officer and Director | 566,500 | 0 | 0 | 531,094 | 21,325 | 6,034,941 |
| 2023-04-27 | 2022 | Anthony J. Doyle Chief Financial Officer and Treasurer | 507,978 | 0 | 361,420 | 203,191 | 15,250 | 2,281,851 |
| 2023-04-27 | 2021 | Anthony J. Doyle Chief Financial Officer and Treasurer | 490,800 | 19,632 | 857,250 | 220,860 | 14,500 | 2,890,803 |
| 2023-04-27 | 2020 | Anthony J. Doyle Chief Financial Officer and Treasurer | 345,455 | 50,000 | 0 | 240,000 | 14,250 | 4,117,930 |
| 2023-04-27 | 2022 | Helen M. Thackray, M.D. Chief R&D Officer | 554,200 | 0 | 861,030 | 277,100 | 12,700 | 3,497,932 |
| 2023-04-27 | 2022 | Alane P. Barnes Chief Legal Officer and Corporate Secretary | 457,200 | 0 | 361,420 | 182,880 | 15,250 | 2,210,762 |
| 2023-04-27 | 2022 | Charles K. Gayer Chief Commercial Officer | 448,700 | 0 | 361,420 | 179,480 | 15,250 | 2,198,862 |
| 2023-04-27 | 2022 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 483,000 | 0 | 680,320 | 193,200 | 15,250 | 2,565,782 |
| 2023-04-27 | 2021 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 458,945 | 18,358 | 400,050 | 206,525 | 14,500 | 2,386,139 |
| 2023-04-27 | 2020 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 445,578 | 0 | 0 | 222,789 | 14,250 | 2,264,785 |
| 2023-04-27 | 2022 | Jon P. Stonehouse President, Chief Executive Officer and Director | 640,000 | 0 | 1,355,325 | 480,000 | 25,415 | 6,982,994 |
| 2023-04-27 | 2020 | William P. Sheridan, MBBS Chief Development Officer | 515,146 | 0 | 0 | 257,573 | 14,250 | 2,679,920 |
| 2023-04-27 | 2021 | William P. Sheridan, MBBS Chief Development Officer | 530,600 | 21,224 | 400,050 | 238,770 | 52,826 | 2,531,231 |
| 2023-04-27 | 2022 | William P. Sheridan, MBBS Chief Development Officer | 549,171 | 0 | 680,320 | 219,668 | 15,250 | 2,658,421 |
| 2022-04-25 | 2021 | Helen M. Thackray, M.D. Chief R&D Officer | 425,125 | 236,500 | 1,519,920 | 298,125 | 6,625 | 6,881,396 |
| 2022-04-25 | 2020 | Anthony J. Doyle Chief Financial Officer | 345,455 | 50,000 | 0 | 240,000 | 14,250 | 4,117,930 |
| 2022-04-25 | 2021 | Anthony J. Doyle Chief Financial Officer | 490,800 | 19,632 | 857,250 | 220,860 | 14,500 | 2,890,803 |
| 2022-04-25 | 2021 | Jon P. Stonehouse President, Chief Executive Officer and Director | 583,495 | 43,762 | 1,405,890 | 492,324 | 24,665 | 7,061,225 |
| 2022-04-25 | 2020 | Jon P. Stonehouse President, Chief Executive Officer and Director | 566,500 | 0 | 0 | 531,094 | 21,325 | 6,034,941 |
| 2022-04-25 | 2019 | Jon P. Stonehouse President, Chief Executive Officer and Director | 550,000 | 0 | 0 | 350,625 | 14,905 | 2,284,297 |
| 2022-04-25 | 2019 | William P. Sheridan, MBBS Chief Medical Officer | 500,142 | 0 | 0 | 170,048 | 14,000 | 1,067,183 |
| 2022-04-25 | 2020 | William P. Sheridan, MBBS Chief Medical Officer | 515,146 | 0 | 0 | 257,573 | 14,250 | 2,679,920 |
| 2022-04-25 | 2021 | William P. Sheridan, MBBS Chief Medical Officer | 530,600 | 21,224 | 400,050 | 238,770 | 52,826 | 2,531,231 |
| 2022-04-25 | 2019 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 432,600 | 0 | 0 | 147,084 | 14,000 | 1,083,307 |
| 2022-04-25 | 2020 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 445,578 | 0 | 0 | 222,789 | 14,250 | 2,264,785 |
| 2022-04-25 | 2021 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 458,945 | 18,358 | 400,050 | 206,525 | 14,500 | 2,386,139 |
| 2022-04-25 | 2019 | Megan T. Sniecinski Former Chief Business Officer | 225,000 | 0 | 0 | 153,000 | 25,590 | 2,176,954 |
| 2022-04-25 | 2020 | Megan T. Sniecinski Former Chief Business Officer | 456,750 | 0 | 0 | 228,375 | 55,825 | 2,012,335 |
| 2022-04-25 | 2021 | Megan T. Sniecinski Former Chief Business Officer | 286,192 | 0 | 0 | 0 | 690,876 | 7,929,124 |
| 2021-04-13 | 2018 | William P. Sheridan, MBBS Chief Medical Officer | 485,574 | 0 | 0 | 208,797 | 28,088 | 2,349,219 |
| 2021-04-13 | 2020 | Megan T. Sniecinski Chief Business Officer | 456,750 | 0 | 0 | 228,375 | 55,825 | 2,012,335 |
| 2021-04-13 | 2019 | Megan T. Sniecinski Chief Business Officer | 225,000 | 0 | 0 | 153,000 | 25,590 | 2,176,954 |
| 2021-04-13 | 2020 | Jon P. Stonehouse President, Chief Executive Officer and Director | 566,500 | 0 | 0 | 531,094 | 21,325 | 6,034,941 |
| 2021-04-13 | 2019 | Jon P. Stonehouse President, Chief Executive Officer and Director | 550,000 | 0 | 0 | 350,625 | 14,905 | 2,284,297 |
| 2021-04-13 | 2018 | Jon P. Stonehouse President, Chief Executive Officer and Director | 550,000 | 0 | 0 | 325,188 | 14,655 | 4,167,643 |
| 2021-04-13 | 2020 | Thomas R. Staab II Former Senior Vice President and Chief Financial Officer | 77,113 | 0 | 0 | 0 | 615,677 | 692,790 |
| 2021-04-13 | 2019 | Thomas R. Staab II Former Senior Vice President and Chief Financial Officer | 462,679 | 0 | 0 | 157,311 | 14,000 | 910,354 |
| 2021-04-13 | 2018 | Thomas R. Staab II Former Senior Vice President and Chief Financial Officer | 449,203 | 0 | 0 | 193,157 | 13,750 | 1,797,270 |
| 2021-04-13 | 2020 | Anthony J. Doyle Chief Financial Officer | 345,455 | 50,000 | 0 | 240,000 | 14,250 | 4,117,930 |
| 2021-04-13 | 2020 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 445,578 | 0 | 0 | 222,789 | 14,250 | 2,264,785 |
| 2021-04-13 | 2019 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 432,600 | 0 | 0 | 147,084 | 14,000 | 1,083,307 |
| 2021-04-13 | 2018 | Yarlagadda S. Babu, Ph.D. Chief Discovery Officer | 420,000 | 0 | 0 | 180,600 | 13,750 | 1,755,510 |
| 2021-04-13 | 2020 | William P. Sheridan, MBBS Chief Medical Officer | 515,146 | 0 | 0 | 257,573 | 14,250 | 2,679,920 |
| 2021-04-13 | 2019 | William P. Sheridan, MBBS Chief Medical Officer | 500,142 | 0 | 0 | 170,048 | 14,000 | 1,067,183 |
| 2020-03-31 | 2017 | William P. Sheridan Senior Vice President and Chief Medical | 469,143 | 155,618 | 0 | 141,429 | 41,072 | 1,808,550 |
| 2020-03-31 | 2019 | Jon P. Stonehouse President, Chief Executive Officer and | 550,000 | 0 | 0 | 350,625 | 14,905 | 2,284,297 |
| 2020-03-31 | 2018 | Jon P. Stonehouse President, Chief Executive Officer and | 550,000 | 0 | 0 | 325,188 | 14,655 | 4,167,643 |
| 2020-03-31 | 2017 | Jon P. Stonehouse President, Chief Executive Officer and | 532,823 | 243,019 | 0 | 220,862 | 14,405 | 3,921,189 |
| 2020-03-31 | 2019 | Thomas R. Staab II Senior Vice President and Chief Financial | 462,679 | 0 | 0 | 157,311 | 14,000 | 910,354 |
| 2020-03-31 | 2018 | Thomas R. Staab II Senior Vice President and Chief Financial | 449,203 | 0 | 0 | 193,157 | 13,750 | 1,797,270 |
| 2020-03-31 | 2017 | Thomas R. Staab II Senior Vice President and Chief Financial | 434,002 | 143,962 | 0 | 130,836 | 13,500 | 1,723,588 |
| 2020-03-31 | 2019 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 432,600 | 0 | 0 | 147,084 | 14,000 | 1,083,307 |
| 2020-03-31 | 2018 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 420,000 | 0 | 0 | 180,600 | 13,750 | 1,755,510 |
| 2020-03-31 | 2017 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 382,480 | 126,872 | 0 | 115,304 | 13,500 | 1,639,444 |
| 2020-03-31 | 2019 | William P. Sheridan Senior Vice President and Chief Medical | 500,142 | 0 | 0 | 170,048 | 14,000 | 1,067,183 |
| 2020-03-31 | 2018 | William P. Sheridan Senior Vice President and Chief Medical | 485,574 | 0 | 0 | 208,797 | 28,088 | 2,349,219 |
| 2020-03-31 | 2019 | Megan T. Sniecinski | 225,000 | 0 | 0 | 153,000 | 25,590 | 2,176,954 |
| 2019-04-17 | 2017 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 369,513 | 122,570 | 0 | 111,395 | 45,066 | 1,487,087 |
| 2019-04-17 | 2018 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 382,454 | 0 | 0 | 164,455 | 59,075 | 1,528,624 |
| 2019-04-17 | 2016 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 360,500 | 0 | 0 | 0 | 29,641 | 672,939 |
| 2019-04-17 | 2016 | William P. Sheridan Senior Vice President and Chief Medical Officer | 457,700 | 0 | 0 | 0 | 36,409 | 818,149 |
| 2019-04-17 | 2017 | William P. Sheridan Senior Vice President and Chief Medical Officer | 469,143 | 155,618 | 0 | 141,429 | 41,072 | 1,808,550 |
| 2019-04-17 | 2018 | William P. Sheridan Senior Vice President and Chief Medical Officer | 485,574 | 0 | 0 | 208,797 | 26,088 | 2,349,219 |
| 2019-04-17 | 2016 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 373,152 | 0 | 0 | 0 | 13,250 | 669,200 |
| 2019-04-17 | 2017 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 382,480 | 126,872 | 0 | 115,304 | 13,500 | 1,639,444 |
| 2019-04-17 | 2018 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 420,000 | 0 | 0 | 180,600 | 13,750 | 1,755,510 |
| 2019-04-17 | 2016 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 423,417 | 0 | 0 | 0 | 13,250 | 719,465 |
| 2019-04-17 | 2017 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 434,002 | 143,962 | 0 | 130,836 | 13,500 | 1,723,588 |
| 2019-04-17 | 2018 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 449,203 | 0 | 0 | 193,157 | 13,750 | 1,797,270 |
| 2019-04-17 | 2016 | Jon P. Stonehouse President, Chief Executive Officer and Director | 519,828 | 0 | 0 | 0 | 14,155 | 1,270,437 |
| 2019-04-17 | 2017 | Jon P. Stonehouse President, Chief Executive Officer and Director | 532,823 | 243,019 | 0 | 220,862 | 14,405 | 3,921,189 |
| 2019-04-17 | 2018 | Jon P. Stonehouse President, Chief Executive Officer and Director | 550,000 | 0 | 0 | 325,188 | 14,655 | 4,167,643 |
| 2018-09-28 | 2017 | William P. Sheridan Senior Vice President and Chief Medical Officer | 469,143 | 155,618 | 0 | 141,429 | 41,072 | 1,808,550 |
| 2018-09-28 | 2017 | Jon P. Stonehouse President, Chief Executive Officer and Director | 532,823 | 243,019 | 0 | 220,862 | 14,405 | 3,921,189 |
| 2018-09-28 | 2015 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 327,564 | 0 | 113,300 | 0 | 61,923 | 3,192,930 |
| 2018-09-28 | 2016 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 360,500 | 0 | 0 | 0 | 29,641 | 672,939 |
| 2018-09-28 | 2017 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 369,513 | 122,570 | 0 | 111,395 | 45,066 | 1,487,087 |
| 2018-09-28 | 2015 | William P. Sheridan Senior Vice President and Chief Medical Officer | 444,369 | 0 | 132,554 | 0 | 50,585 | 1,568,570 |
| 2018-09-28 | 2016 | Jon P. Stonehouse President, Chief Executive Officer and Director | 519,828 | 0 | 0 | 0 | 14,155 | 1,270,437 |
| 2018-09-28 | 2015 | Jon P. Stonehouse President, Chief Executive Officer and Director | 504,687 | 0 | 345,344 | 0 | 14,155 | 3,149,178 |
| 2018-09-28 | 2017 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 434,002 | 143,962 | 0 | 130,836 | 13,500 | 1,723,588 |
| 2018-09-28 | 2016 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 423,417 | 0 | 0 | 0 | 13,250 | 719,465 |
| 2018-09-28 | 2015 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 411,084 | 0 | 108,224 | 0 | 13,250 | 1,328,975 |
| 2018-09-28 | 2016 | William P. Sheridan Senior Vice President and Chief Medical Officer | 457,700 | 0 | 0 | 0 | 36,409 | 818,149 |
| 2018-09-28 | 2017 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 382,480 | 126,872 | 0 | 115,304 | 13,500 | 1,639,444 |
| 2018-09-28 | 2016 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 373,152 | 0 | 0 | 0 | 13,250 | 669,200 |
| 2018-09-28 | 2015 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 362,283 | 0 | 108,224 | 0 | 13,250 | 1,280,174 |
| 2018-05-10 | 2017 | Jon P. Stonehouse President, Chief Executive Officer and Director | 532,823 | 243,019 | 0 | 220,862 | 14,405 | 3,921,189 |
| 2018-05-10 | 2015 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 327,564 | 0 | 113,300 | 0 | 61,923 | 3,192,930 |
| 2018-05-10 | 2016 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 360,500 | 0 | 0 | 0 | 29,641 | 672,939 |
| 2018-05-10 | 2017 | Lynne M. Powell Senior Vice President and Chief Commercial Officer | 369,513 | 122,570 | 0 | 111,395 | 45,066 | 1,487,087 |
| 2018-05-10 | 2015 | William P. Sheridan Senior Vice President and Chief Medical Officer | 444,369 | 0 | 132,554 | 0 | 50,585 | 1,568,570 |
| 2018-05-10 | 2016 | William P. Sheridan Senior Vice President and Chief Medical Officer | 457,700 | 0 | 0 | 0 | 36,409 | 818,149 |
| 2018-05-10 | 2017 | William P. Sheridan Senior Vice President and Chief Medical Officer | 469,143 | 155,618 | 0 | 141,429 | 41,072 | 1,808,550 |
| 2018-05-10 | 2015 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 362,283 | 0 | 108,224 | 0 | 13,250 | 1,280,174 |
| 2018-05-10 | 2016 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 373,152 | 0 | 0 | 0 | 13,250 | 669,200 |
| 2018-05-10 | 2017 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 382,480 | 126,872 | 0 | 115,304 | 13,500 | 1,639,444 |
| 2018-05-10 | 2015 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 411,084 | 0 | 108,224 | 0 | 13,250 | 1,328,975 |
| 2018-05-10 | 2016 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 423,417 | 0 | 0 | 0 | 13,250 | 719,465 |
| 2018-05-10 | 2017 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 434,002 | 143,962 | 0 | 130,836 | 13,500 | 1,723,588 |
| 2018-05-10 | 2015 | Jon P. Stonehouse President, Chief Executive Officer and Director | 504,687 | 0 | 345,344 | 0 | 14,155 | 3,149,178 |
| 2018-05-10 | 2016 | Jon P. Stonehouse President, Chief Executive Officer and Director | 519,828 | 0 | 0 | 0 | 14,155 | 1,270,437 |
| 2017-04-12 | 2014 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 399,120 | 62,308 | 583,200 | 113,747 | 13,000 | 2,145,788 |
| 2017-04-12 | 2016 | Jon P. Stonehouse President, Chief Executive Officer and Director | 519,828 | 0 | 0 | 0 | 14,155 | 1,270,437 |
| 2017-04-12 | 2015 | Jon P. Stonehouse President, Chief Executive Officer and Director | 504,687 | 0 | 345,344 | 0 | 14,155 | 3,149,178 |
| 2017-04-12 | 2014 | Jon P. Stonehouse President, Chief Executive Officer and Director | 506,202 | 127,491 | 1,382,400 | 232,744 | 13,905 | 2,903,292 |
| 2017-04-12 | 2016 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 423,417 | 0 | 0 | 0 | 13,250 | 719,465 |
| 2017-04-12 | 2015 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 411,084 | 0 | 108,224 | 0 | 13,250 | 1,328,975 |
| 2017-04-12 | 2016 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 373,152 | 0 | 0 | 0 | 13,250 | 669,200 |
| 2017-04-12 | 2015 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 362,283 | 0 | 108,224 | 0 | 13,250 | 1,280,174 |
| 2017-04-12 | 2014 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 405,854 | 54,911 | 583,200 | 100,243 | 13,000 | 2,131,621 |
| 2017-04-12 | 2016 | William P. Sheridan Senior Vice President and Chief Medical Officer | 457,700 | 0 | 0 | 0 | 36,409 | 818,149 |
| 2017-04-12 | 2015 | William P. Sheridan Senior Vice President and Chief Medical Officer | 444,369 | 0 | 132,554 | 0 | 50,585 | 1,568,570 |
| 2017-04-12 | 2014 | William P. Sheridan Senior Vice President and Chief Medical Officer | 436,433 | 67,352 | 583,200 | 122,956 | 25,430 | 2,390,594 |
| 2017-04-12 | 2016 | Lynne M. Powell Senior Vice President and | 360,500 | 0 | 0 | 0 | 29,641 | 672,939 |
| 2017-04-12 | 2015 | Lynne M. Powell Senior Vice President and | 327,564 | 0 | 113,300 | 0 | 61,923 | 3,192,930 |
| 2016-04-11 | 2015 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 411,084 | 0 | 108,224 | 0 | 13,250 | 1,328,975 |
| 2016-04-11 | 2013 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 387,486 | 0 | 24,140 | 81,372 | 12,750 | 1,179,713 |
| 2016-04-11 | 2015 | Lynne M. Powell | 327,564 | 0 | 113,300 | 0 | 61,923 | 3,192,930 |
| 2016-04-11 | 2013 | William P. Sheridan Senior Vice President and Chief Medical Officer | 418,860 | 0 | 24,140 | 87,961 | 21,431 | 1,226,357 |
| 2016-04-11 | 2014 | William P. Sheridan Senior Vice President and Chief Medical Officer | 436,433 | 67,352 | 583,200 | 122,956 | 25,430 | 2,390,594 |
| 2016-04-11 | 2015 | William P. Sheridan Senior Vice President and Chief Medical Officer | 444,369 | 0 | 132,554 | 0 | 50,585 | 1,568,570 |
| 2016-04-11 | 2014 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 405,854 | 54,911 | 583,200 | 100,243 | 13,000 | 2,131,621 |
| 2016-04-11 | 2014 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 399,120 | 62,308 | 583,200 | 113,747 | 13,000 | 2,145,788 |
| 2016-04-11 | 2015 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 362,283 | 0 | 108,224 | 0 | 13,250 | 1,280,174 |
| 2016-04-11 | 2015 | Jon P. Stonehouse President, Chief Executive Officer and Director | 504,687 | 0 | 345,344 | 0 | 14,155 | 3,149,178 |
| 2016-04-11 | 2014 | Jon P. Stonehouse President, Chief Executive Officer and Director | 506,202 | 127,491 | 1,382,400 | 232,744 | 13,905 | 2,903,292 |
| 2016-04-11 | 2013 | Jon P. Stonehouse President, Chief Executive Officer and Director | 475,716 | 0 | 88,892 | 166,501 | 13,655 | 1,975,287 |
| 2015-04-10 | 2012 | William P. Sheridan Senior Vice President and Chief Medical Officer | 405,330 | 0 | 40,205 | 0 | 12,500 | 1,017,540 |
| 2015-04-10 | 2013 | Alane P. Barnes Vice President, General Counsel and Corporate Secretary | 231,709 | 0 | 24,140 | 48,659 | 11,586 | 990,059 |
| 2015-04-10 | 2014 | Alane P. Barnes Vice President, General Counsel and Corporate Secretary | 279,560 | 46,741 | 291,600 | 75,525 | 13,000 | 1,331,087 |
| 2015-04-10 | 2014 | Jon P. Stonehouse President, Chief Executive Officer and Director | 506,202 | 127,491 | 1,382,400 | 232,744 | 13,905 | 2,903,292 |
| 2015-04-10 | 2013 | Jon P. Stonehouse President, Chief Executive Officer and Director | 475,716 | 0 | 88,892 | 166,501 | 13,655 | 1,975,287 |
| 2015-04-10 | 2012 | Jon P. Stonehouse President, Chief Executive Officer and Director | 461,860 | 0 | 157,287 | 0 | 13,405 | 1,244,628 |
| 2015-04-10 | 2014 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 399,120 | 62,308 | 583,200 | 113,747 | 13,000 | 2,145,788 |
| 2015-04-10 | 2013 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 387,486 | 0 | 24,140 | 81,372 | 12,750 | 1,179,713 |
| 2015-04-10 | 2012 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 375,167 | 0 | 26,488 | 0 | 12,500 | 517,277 |
| 2015-04-10 | 2014 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 405,854 | 54,911 | 583,200 | 100,243 | 13,000 | 2,131,621 |
| 2015-04-10 | 2013 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 341,486 | 0 | 24,140 | 71,712 | 12,750 | 1,124,053 |
| 2015-04-10 | 2014 | William P. Sheridan Senior Vice President and Chief Medical Officer | 436,433 | 67,352 | 583,200 | 122,956 | 25,430 | 2,390,594 |
| 2015-04-10 | 2013 | William P. Sheridan Senior Vice President and Chief Medical Officer | 418,860 | 0 | 24,140 | 87,961 | 21,431 | 1,226,357 |
| 2014-03-21 | 2012 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 330,455 | 0 | 52,976 | 0 | 12,500 | 602,174 |
| 2014-03-21 | 2011 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 323,452 | 0 | 37,350 | 110,028 | 12,250 | 621,580 |
| 2014-03-21 | 2013 | William P. Sheridan Senior Vice President and Chief Medical Officer | 418,860 | 0 | 24,140 | 87,961 | 21,431 | 1,226,357 |
| 2014-03-21 | 2012 | William P. Sheridan Senior Vice President and Chief Medical Officer | 405,330 | 0 | 40,205 | 0 | 12,500 | 1,017,540 |
| 2014-03-21 | 2011 | William P. Sheridan Senior Vice President and Chief Medical Officer | 396,743 | 0 | 41,500 | 119,604 | 12,250 | 722,447 |
| 2014-03-21 | 2013 | Alane P. Barnes | 231,709 | 0 | 24,140 | 48,659 | 11,586 | 990,059 |
| 2014-03-21 | 2013 | Jon P. Stonehouse President, Chief Executive Officer and Director | 475,716 | 0 | 88,892 | 166,501 | 13,655 | 1,975,287 |
| 2014-03-21 | 2012 | Jon P. Stonehouse President, Chief Executive Officer and Director | 461,860 | 0 | 157,287 | 0 | 13,655 | 1,244,878 |
| 2014-03-21 | 2011 | Jon P. Stonehouse President, Chief Executive Officer and Director | 459,617 | 0 | 118,275 | 219,383 | 13,655 | 1,276,290 |
| 2014-03-21 | 2013 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 387,486 | 0 | 24,140 | 81,372 | 12,750 | 1,179,713 |
| 2014-03-21 | 2012 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 375,167 | 0 | 26,488 | 0 | 12,500 | 517,277 |
| 2014-03-21 | 2011 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 185,000 | 0 | 94,500 | 62,702 | 0 | 842,202 |
| 2014-03-21 | 2013 | Yarlagadda S. Babu, Ph.D. Senior Vice President of Drug Discovery | 341,486 | 0 | 24,140 | 71,712 | 12,750 | 1,124,053 |
| 2013-04-16 | 2011 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 323,452 | 0 | 37,350 | 110,028 | 12,250 | 621,580 |
| 2013-04-16 | 2012 | Jon P. Stonehouse President, Chief Executive Officer and Director | 461,860 | 0 | 157,287 | 0 | 12,500 | 1,243,723 |
| 2013-04-16 | 2011 | Jon P. Stonehouse President, Chief Executive Officer and Director | 459,617 | 0 | 118,275 | 219,383 | 12,250 | 1,274,885 |
| 2013-04-16 | 2010 | Jon P. Stonehouse President, Chief Executive Officer and Director | 448,400 | 0 | 0 | 161,424 | 12,250 | 1,211,071 |
| 2013-04-16 | 2012 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 375,167 | 0 | 26,488 | 0 | 12,500 | 517,277 |
| 2013-04-16 | 2011 | Thomas R. Staab II Senior Vice President and Chief Financial Officer | 185,000 | 0 | 94,500 | 62,702 | 0 | 842,202 |
| 2013-04-16 | 2012 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 330,455 | 0 | 52,976 | 0 | 12,500 | 602,174 |
| 2013-04-16 | 2010 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 315,560 | 0 | 0 | 68,161 | 12,250 | 621,243 |
| 2013-04-16 | 2012 | William P. Sheridan Senior Vice President and Chief Medical Officer | 405,330 | 0 | 40,205 | 0 | 12,500 | 1,017,540 |
| 2013-04-16 | 2011 | William P. Sheridan Senior Vice President and Chief Medical Officer | 396,743 | 0 | 41,500 | 119,604 | 12,250 | 722,447 |
| 2013-04-16 | 2010 | William P. Sheridan Senior Vice President and Chief Medical Officer | 387,060 | 0 | 0 | 83,605 | 12,250 | 745,052 |
| 2013-04-16 | 2012 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 269,741 | 0 | 40,205 | 0 | 6,392 | 482,663 |
| 2013-04-16 | 2011 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 269,417 | 0 | 24,900 | 81,091 | 12,250 | 498,458 |
| 2013-04-16 | 2010 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 265,000 | 0 | 0 | 43,725 | 12,250 | 546,252 |
| 2012-04-09 | 2009 | Stuart Grant Former Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2011 | Jon P. Stonehouse President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2010 | Jon P. Stonehouse President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2009 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2011 | William P. Sheridan Senior Vice President and Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2010 | William P. Sheridan Senior Vice President and Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2010 | Stuart Grant Former Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2009 | William P. Sheridan Senior Vice President and Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2011 | Stuart Grant Former Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2011 | Thomas R. Staab II | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2009 | Jon P. Stonehouse President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2010 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2011 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2010 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 0 | 0 | 0 | 0 | 0 | 0 |
| 2012-04-09 | 2011 | Yarlagadda S. Babu, Ph.D. Vice President, Drug Discovery | 0 | 0 | 0 | 0 | 0 | 0 |
| 2011-04-05 | 2010 | Peter L. McCullough Vice President, Operations | 260,000 | 40,000 | 0 | 57,330 | 32,334 | 664,638 |
| 2011-04-05 | 2010 | William P. Sheridan Senior Vice President and Chief Medical Officer | 387,060 | 0 | 0 | 83,605 | 12,250 | 745,052 |
| 2011-04-05 | 2008 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 222,936 | 0 | 45,050 | 58,400 | 11,250 | 373,689 |
| 2011-04-05 | 2009 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 236,507 | 179,616 | 0 | 68,900 | 12,250 | 560,273 |
| 2011-04-05 | 2010 | David S. McCullough Vice President, Strategic Planning, Commercialization and Corporate Development | 265,000 | 0 | 0 | 43,725 | 12,250 | 546,252 |
| 2011-04-05 | 2008 | Yarlagadda S. Babu, Ph.D Vice President, Drug Discovery | 300,102 | 0 | 60,881 | 85,000 | 11,250 | 519,933 |
| 2011-04-05 | 2009 | Yarlagadda S. Babu, Ph.D Vice President, Drug Discovery | 313,537 | 242,736 | 0 | 75,734 | 12,250 | 734,257 |
| 2011-04-05 | 2010 | Yarlagadda S. Babu, Ph.D Vice President, Drug Discovery | 315,560 | 0 | 0 | 68,161 | 12,250 | 621,243 |
| 2011-04-05 | 2008 | Stuart Grant Senior Vice President and Chief Financial Officer | 384,375 | 0 | 77,498 | 115,900 | 13,101 | 747,624 |
| 2011-04-05 | 2009 | Stuart Grant Senior Vice President and Chief Financial Officer | 403,958 | 309,000 | 0 | 122,250 | 0 | 947,708 |
| 2011-04-05 | 2010 | Stuart Grant Senior Vice President and Chief Financial Officer | 407,500 | 0 | 0 | 97,000 | 0 | 688,815 |
| 2011-04-05 | 2009 | William P. Sheridan Senior Vice President and Chief Medical Officer | 385,050 | 0 | 0 | 92,894 | 12,250 | 510,444 |
| 2011-04-05 | 2008 | Jon P. Stonehouse President, Chief Executive Officer and Director | 420,835 | 0 | 0 | 180,700 | 11,250 | 739,753 |
| 2011-04-05 | 2009 | Jon P. Stonehouse President, Chief Executive Officer and Director | 444,500 | 0 | 0 | 208,506 | 12,250 | 916,896 |
| 2011-04-05 | 2010 | Jon P. Stonehouse President, Chief Executive Officer and Director | 448,400 | 0 | 0 | 161,424 | 12,250 | 1,211,071 |
| 2011-04-05 | 2008 | William P. Sheridan Senior Vice President and Chief Medical Officer | 187,500 | 0 | 0 | 52,500 | 31,526 | 605,526 |
| 2010-04-06 | 2009 | Yarlagadda S. Babu, Ph.D, Vice President, Drug Discovery | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2009 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2008 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2007 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2009 | Stuart Grant, Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2008 | Stuart Grant, Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2007 | Stuart Grant, Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2009 | William P. Sheridan, Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2008 | William P. Sheridan, Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2008 | Yarlagadda S. Babu, Ph.D, Vice President, Drug Discovery | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2009 | David S. McCullough, Vice President, Strategic Planning and Commercialization | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2008 | David S. McCullough, Vice President, Strategic Planning and Commercialization | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-04-06 | 2007 | David S. McCullough, Vice President, Strategic Planning and Commercialization | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2008 | William P. Sheridan, Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2006 | David S. McCullough, Vice President, Strategic Planning and | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2007 | David S. McCullough, Vice President, Strategic Planning and | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2008 | David S. McCullough, Vice President, Strategic Planning and | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2007 | Yarlagadda S. Babu, Ph.D, Vice President, Drug Discovery | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2006 | Stuart Grant, Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2007 | Stuart Grant, Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2008 | Stuart Grant, Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2008 | Yarlagadda S. Babu, Ph.D, Vice President, Drug Discovery | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2006 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2007 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2008 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2006 | J. Claude Bennett, M.D., Former Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2007 | J. Claude Bennett, M.D., Former Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2008 | J. Claude Bennett, M.D., Former Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-04-03 | 2007 | William P. Sheridan, Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2008-04-16 | 2007 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 394,110 | 0 | 147,625 | 110,000 | 12,875 | 1,540,985 |
| 2008-04-16 | 2006 | Jon P. Stonehouse, President, Chief Executive Officer and Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2008-04-16 | 2007 | Charles E. Bugg, Ph.D., Former Chief Executive Officer | 170,991 | 0 | 0 | 0 | 68,582 | 494,400 |
| 2008-04-16 | 2006 | Charles E. Bugg, Ph.D., Former Chief Executive Officer | 453,384 | 0 | 0 | 0 | 11,000 | 702,129 |
| 2008-04-16 | 2007 | Stuart Grant, Senior Vice President and Chief Financial Officer | 132,212 | 0 | 0 | 39,250 | 36,016 | 359,770 |
| 2008-04-16 | 2006 | Stuart Grant, Senior Vice President and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2008-04-16 | 2007 | Michael A. Darwin, Vice President Finance & Treasurer (Former Chief Financial Officer) | 235,519 | 25,000 | 0 | 21,717 | 11,250 | 424,303 |
| 2008-04-16 | 2006 | Michael A. Darwin, Vice President Finance & Treasurer (Former Chief Financial Officer) | 224,232 | 0 | 0 | 0 | 11,000 | 351,660 |
| 2008-04-16 | 2007 | J. Claude Bennett, M.D., Chief Operating Officer | 360,912 | 25,000 | 0 | 36,091 | 11,250 | 633,923 |
| 2008-04-16 | 2006 | J. Claude Bennett, M.D., Chief Operating Officer | 347,016 | 0 | 0 | 0 | 11,000 | 530,838 |
| 2008-04-16 | 2007 | W. James Alexander, M.D., MPH, Senior Vice President and Chief Medical Officer | 335,040 | 65,000 | 0 | 0 | 11,250 | 1,093,969 |
| 2008-04-16 | 2006 | W. James Alexander, M.D., MPH, Senior Vice President and Chief Medical Officer | 172,317 | 90,000 | 0 | 0 | 4,000 | 654,380 |
| 2008-04-16 | 2007 | Randall B. Riggs, Senior Vice President Business Development | 250,810 | 25,000 | 0 | 0 | 11,250 | 460,725 |
| 2008-04-16 | 2006 | Randall B. Riggs, Senior Vice President Business Development | 290,016 | 60,000 | 0 | 0 | 11,000 | 619,237 |
| 2008-04-16 | 2007 | David S. McCullough, Vice President, Strategic Planning and Commercialization | 161,262 | 0 | 15,375 | 33,252 | 0 | 357,545 |
| 2008-04-16 | 2006 | David S. McCullough, Vice President, Strategic Planning and Commercialization | 0 | 0 | 0 | 0 | 0 | 0 |
| 2007-04-10 | 2006 | Randall B. Riggs, Senior Vice President Business Development | 290,016 | 60,000 | 0 | 0 | 11,420 | 619,657 |
| 2007-04-10 | 2006 | W. James Alexander, M.D., MPH, Senior Vice President and Chief Medical Officer | 172,317 | 90,000 | 0 | 0 | 4,260 | 654,640 |
| 2007-04-10 | 2006 | Michael A. Darwin , Chief Financial Officer, Secretary & Treasurer | 224,232 | 0 | 0 | 0 | 11,420 | 352,080 |
| 2007-04-10 | 2006 | J. Claude Bennett, M.D., President and Chief Operating Officer | 347,016 | 0 | 0 | 0 | 11,210 | 531,048 |
| 2007-04-10 | 2006 | Charles E. Bugg, Ph.D., Chairman and Chief Executive Officer | 453,384 | 0 | 0 | 0 | 11,347 | 702,476 |
| 2006-04-10 | 2005 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 202,518 | 27,386 | 0 | 0 | 10,628 | 240,532 |
| 2006-04-10 | 2004 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 168,972 | 0 | 0 | 0 | 49,273 | 218,245 |
| 2006-04-10 | 2003 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 142,710 | 0 | 0 | 0 | 6,990 | 149,700 |
| 2006-04-10 | 2005 | Randall B. Riggs | 212,500 | 75,000 | 0 | 0 | 10,680 | 298,180 |
| 2006-04-10 | 2005 | Jonathan M. P. Nugent | 117,589 | 23,474 | 0 | 0 | 27,151 | 168,214 |
| 2006-04-10 | 2004 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 304,512 | 0 | 0 | 0 | 11,834 | 316,346 |
| 2006-04-10 | 2005 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 325,008 | 42,384 | 0 | 0 | 12,354 | 379,746 |
| 2006-04-10 | 2003 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 300,000 | 484,500 | 0 | 0 | 11,584 | 796,084 |
| 2006-04-10 | 2004 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 400,008 | 0 | 0 | 0 | 426,300 | 826,308 |
| 2006-04-10 | 2005 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 425,016 | 55,374 | 0 | 0 | 119,280 | 599,670 |
| 2006-04-10 | 2003 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 228,384 | 0 | 0 | 0 | 12,781 | 241,165 |
| 2005-04-06 | 2002 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2003 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2004 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2002 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2004 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2003 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2002 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2003 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-06 | 2004 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| 2004-04-12 | 2003 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 142,710 | 0 | 0 | 0 | 6,990 | 149,700 |
| 2004-04-12 | 2001 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 79,512 | 0 | 0 | 0 | 876 | 80,388 |
| 2004-04-12 | 2001 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 381,576 | 0 | 0 | 0 | 8,500 | 390,076 |
| 2004-04-12 | 2002 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 359,922 | 0 | 0 | 0 | 10,251 | 370,173 |
| 2004-04-12 | 2003 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 300,000 | 484,500 | 0 | 0 | 11,584 | 796,084 |
| 2004-04-12 | 2003 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 228,384 | 0 | 0 | 0 | 12,781 | 241,165 |
| 2004-04-12 | 2002 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 274,507 | 0 | 0 | 0 | 11,166 | 285,673 |
| 2004-04-12 | 2001 | J. Claude Bennett, M.D. President, Chief Operating Officer and Medical Director | 291,707 | 15,000 | 0 | 0 | 8,500 | 315,207 |
| 2004-04-12 | 2002 | Michael A. Darwin Chief Financial Officer, Treasurer and Secretary | 89,168 | 0 | 0 | 0 | 240 | 89,408 |
| 2003-03-27 | 2001 | J. Claude Bennett, M.D. President, Chief Operating Officer and | 291,707 | 15,000 | 0 | 0 | 8,500 | 315,207 |
| 2003-03-27 | 2000 | J. Claude Bennett, M.D. President, Chief Operating Officer and | 264,480 | 0 | 0 | 0 | 8,250 | 272,730 |
| 2003-03-27 | 2002 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 359,922 | 0 | 0 | 0 | 10,251 | 370,173 |
| 2003-03-27 | 2001 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 381,576 | 0 | 0 | 0 | 8,500 | 390,076 |
| 2003-03-27 | 2000 | Charles E. Bugg, Ph.D. Chairman and Chief Executive Officer | 355,465 | 60,000 | 0 | 0 | 8,250 | 423,715 |
| 2003-03-27 | 2002 | J. Claude Bennett, M.D. President, Chief Operating Officer and | 274,507 | 20 | 0 | 0 | 211,166 | 485,693 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
